Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Dermatology Reports
Erschienen in: Current Dermatology Reports 1/2019

30.01.2019 | Psoriasis (J Wu, Section Editor)

Nanotechnology for Psoriasis Therapy

verfasst von: Emily C. Murphy, Samuel W. Schaffter, Adam J. Friedman

Erschienen in: Current Dermatology Reports | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

To summarize the use of nanotechnology-based drug delivery systems for psoriasis therapies, focusing on recent studies of treatment efficacy in humans and murine models.

Recent Findings

Both topical and oral psoriasis medications, in addition to alternative psoriasis therapies and siRNAs targeting genes involved in the pathogenesis of psoriasis, have been incorporated into nanocarriers. Numerous studies demonstrate that nanocarriers can enhance the efficacy and reduce side effects of their included drugs through increased skin retention, sustained release, and decreased systemic absorption. However, the number of studies in humans is limited and while the short-term use of nanocarriers appears safe, long-term outcomes are unknown. Additionally, few studies compare different types of nanocarriers, making it difficult to recommend which types of nanocarriers are the best.

Summary

While recent research has demonstrated the benefit of nanotechnology-based drug delivery systems for psoriasis, more research, especially in humans, is needed to optimize drug-loaded nanocarriers for clinical use.
Literatur
1.
Parisi R, Symmons DP, CEM G, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol. 2012;133:377.PubMed
2.
Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–59.PubMed
3.
Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62:114–35.PubMed
4.
5.
Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451–85.PubMed
6.
7.
Garg. Nanotechnological approaches for the effective management of psoriasis. Artif Cells Nanomed Biotechnol. 2016;44:1374–82.PubMed
8.
Rahman. Nanomedicine-based drug targeting for psoriasis: potentials and emerging trends in nanoscale pharmacotherapy. Expert Opin Drug Deliv. 2015;12:635–52.PubMed
9.
Wan T, Pan W, Long Y, Yu K, Liu S, Ruan W, et al. Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: permeability through psoriatic skin and antipsoriatic and antiproliferative activities. Int J Nanomed. 2017;12:1485–97.
10.
Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3:16–20.PubMed
11.
de Leeuw J, de Vijlder HC, Bjerring P, Neumann H a M. Liposomes in dermatology today. J Eur Acad Dermatol Venereol. 2009;23:505–16.PubMed
12.
• Raza K, Singh B, Lohan S, Sharma G, Negi P, Yachha Y, et al. Nano-lipoidal carriers of tretinoin with enhanced percutaneous absorption, photostability, biocompatibility and anti-psoriatic activity. Int J Pharm. 2013;456:65–72 Compared skin retention and anti-psoriatic efficacy of tretinoin-loaded liposomes, ethosomes, solid lipid nanoparticles, and nanostructured lipid carriers in a murine model. This is one of the few studies comparing carriers against each other rather than to marketed products. The liposomes and nanostructured lipid carriers led to the highest tretinoin skin retention and efficacy.PubMed
13.
•• Abdelgawad R, Maha N, Mofta N, Hamza M. Phospholipid membrane tubulation using ceramide doping “cerosomes”: characterization and clinical application in psoriasis treatment. Eur J Pharm Sci : official journal of the European Federation for Pharmaceutical Sciences. 2017;101:258–68 Vesicular carriers including both tazarotene and ceramide improved psoriasis symptoms more than both commercial tazarotene gel and tazarotene-loaded vesicular carriers without ceramides in a randomized, controlled trial with 20 patients. This is one of the few trials with human participants.
14.
•• Kumar R, Dogra S, Amarji B, Singh B, Kumar S, null S, et al. Efficacy of novel topical liposomal formulation of cyclosporine in mild to moderate stable plaque psoriasis: a randomized clinical trial. JAMA Dermatol. 2016;152:807–15 Cyclosporine-loaded liposomes were used to treat 38 patients in this double-blind, randomized controlled trial. Cyclosporine-liposomes resulted in higher plaque clearance than a commercial cyclosporine cream but lower clearance than clobetasol propionate. No systemic cyclosporine absorption was detected with blood sampling in patients treated with cyclosporine-liposomes. PubMed
15.
Doppalapudi S, Jain A, Chopra DK, Khan W. Psoralen loaded liposomal nanocarriers for improved skin penetration and efficacy of topical PUVA in psoriasis. Eur J Pharm Sci. 2017;96:515–29.PubMed
16.
Anderson M, Omri A. The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations. Drug Delivery. 2004;11:33–9.PubMed
17.
Zhang Y-T, Shen L-N, Zhao J-H, Feng N-P. Evaluation of psoralen ethosomes for topical delivery in rats by using in vivo microdialysis. Int J Nanomedicine. 2014;9:669–78.PubMedPubMedCentral
18.
Patel R, Singh SK, Singh S, Sheth N, Gendle R. Development and Characterization of Curcumin Loaded Transfersome for Transdermal Delivery. J Pharm Sci Res. 2009;1(4):71–80.
19.
Abdelbary A, AbouGhaly M. Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: application of Box–Behnken design, in-vitro evaluation and in-vivo skin deposition study. Int J Pharm. 2015;485:235–43.PubMed
20.
Bhatia A, Singh B, Wadhwa S, Raza K, Katare OP. Novel phospholipid-based topical formulations of tamoxifen: evaluation for antipsoriatic activity using mouse-tail model. Pharm Dev Technol. 2014;19(2):160–3.PubMed
21.
Khandavilli S, Panchagnula R. Nanoemulsions as versatile formulations for paclitaxel delivery: peroral and dermal delivery studies in rats. J Investig Dermatol. 2007;127:154–62.PubMed
22.
Bracke S, Carretero M, Guerrero-Aspizua S, Desmet E, Illera N, Navarro M, et al. Targeted silencing of DEFB4 in a bioengineered skin-humanized mouse model for psoriasis: development of siRNA SECosome-based novel therapies. Exp Dermatol. 2014;23:199–201.PubMed
23.
Namdeo A, Jain N. Niosomes as drug carriers. Indian J Pharm Sci. 1996;58:41–6.
24.
Abu Hashim II, Abo El-Magd NF, El-Sheakh AR, Hamed MF, Abd El-Gawad AE-GH. Pivotal role of Acitretin nanovesicular gel for effective treatment of psoriasis: ex vivo-in vivo evaluation study. Int J Nanomed. 2018;13:1059–79.
25.
Letchford K, Burt H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm. 2007;65:259–69.PubMed
26.
Photos PJ, Bacakova L, Discher B, Bates FS, Discher DE. Polymer vesicles in vivo: correlations with PEG molecular weight. J Control Release. 2003;90:323–34.PubMed
27.
Marepally S, Boakye CHA, Patel AR, Godugu C, Doddapaneni R, Desai PR, et al. Topical administration of dual siRNAs using fusogenic lipid nanoparticles for treating psoriatic-like plaques. Nanomedicine (London). 2014;9:2157–74.
28.
Thakur A, Walia MK, Kumar SLH. Nanoemulsion in enhancement of bioavailability of poorly soluble drugs: a review. Pharmacophore. 2013;4(1):15–25.
29.
Musa SH, Basri M, Fard Masoumi HR, Shamsudin N, Salim N. Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: in vitro diffusion and in vivo hydrating action. Int J Nanomedicine. 2017;12:2427–41.PubMedPubMedCentral
30.
• Kaur A, Katiyar SS, Kushwah V, Jain S. Nanoemulsion loaded gel for topical co-delivery of clobitasol propionate and calcipotriol in psoriasis. Nanomedicine. 2017;13:1473–82 Examined efficacy of a nanogel including both clobetasol propionate and calcipotriol highlighting the ability to combine multiple drugs in nanocarriers. The drug-loaded nanogel led to increased drug retention and anti-psoriatic efficacy compared to free drugs.PubMed
31.
Hemmila MR, Mattar A, Taddonio MA, Arbabi S, Hamouda T, Ward PA, et al. Topical nanoemulsion therapy reduces bacterial wound infection and inflammation after burn injury. Surgery. 2010;148:499–509.PubMedPubMedCentral
32.
Alam MS, Ali MS, Alam N, Siddiqui MR, Shamim M, Safhi MM. In vivo study of clobetasol propionate loaded nanoemulsion for topical application in psoriasis and atopic dermatitis. Drug Invention Today. 2013;5:8–12.
33.
Küchler S, Herrmann W, Panek-Minkin G, Blaschke T, Zoschke C, Kramer KD, et al. SLN for topical application in skin diseases—characterization of drug-carrier and carrier-target interactions. Int J Pharm. 2010;390:225–33.PubMed
34.
Morganti P. Use and potential of nanotechnology in cosmetic dermatology. Clinical, cosmetic and investigational dermatology : CCID. 2010;3:5–13.PubMed
35.
Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161–77.PubMed
36.
Fang C-L, Al-Suwayeh SA, Fang J-Y. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol. 2013;7:41–55.PubMed
37.
Agrawal U, Gupta M, Vyas SP. Capsaicin delivery into the skin with lipidic nanoparticles for the treatment of psoriasis. Artificial Cells, Nanomedicine, And Biotechnology. 2015;43:33–9.PubMed
38.
Raza K, Katare O, Setia A, Bhatia A, Singh B. Improved therapeutic performance of dithranol against psoriasis employing systematically optimized nanoemulsomes. J Microencapsul. 2013;30:225–36.PubMed
39.
Zhou X, Chen Z. Preparation and performance evaluation of emulsomes as a drug delivery system for silybin. Arch Pharm Res. 2015;38:2193–200.PubMed
40.
Bessar H, Venditti I, Benassi L, Vaschieri C, Azzoni P, Pellacani G, et al. Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. Colloids Surf B: Biointerfaces. 2016;141:141–7.PubMed
41.
• Nemati H, Ghahramani M-H, Faridi-Majidi R, Izadi B, Bahrami G, Madani S-H, et al. Using siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation in psoriasis. J Control Release. 2017;268:259–68 EGFR siRNA was conjugated to gold nanoparticles and efficacy was examined in an imiquimod-induced murine model. Use of the EGFR siRNA-AuNPs led to reduced T cell markers and epidermal thickness compared to nonsense siRNA-AuNPs and free EGFR siRNA, respectively. This highlights the success of siRNA treatment for psorasis, meaning that many other genes involved in psoriasis could also be targeted. PubMed
42.
Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001;70:1–20.PubMed
43.
Chamcheu JC, Siddiqui IA, Adhami VM, Esnault S, Bharali DJ, Babatunde AS, et al. Chitosan-based nanoformulated (−)-epigallocatechin-3-gallate (EGCG) modulates human keratinocyte-induced responses and alleviates imiquimod-induced murine psoriasiform dermatitis. Int J Nanomedicine. 2018;13:4189–206.PubMedPubMedCentral
44.
Mao K-L, Fan Z-L, Yuan J-D, Chen PP, Yang JJ, Xu J, et al. Skin-penetrating polymeric nanoparticles incorporated in silk fibroin hydrogel for topical delivery of curcumin to improve its therapeutic effect on psoriasis mouse model. Colloids Surf B: Biointerfaces. 2017;160:704–14.PubMed
45.
Kabanov AV, Vinogradov SV. Nanogels as pharmaceutical carriers: finite networks of infinite capabilities. Angew Chem Int Ed. 2009;48:5418–29.
46.
• Divya G, Panonnummal R, Gupta S, Jayakumar R, Sabitha M. Acitretin and aloe-emodin loaded chitin nanogel for the treatment of psoriasis. Eur J Pharm Biopharm. 2016;107:97–109 Created nanogels loaded with acitretin and a complementary therapy, aloe-emodin (an Aloe vera extract). Application of these two nanogels produced greater efficacy than a commercial tacrolimus cream showing that you can also apply multiple nanocarrier formulations, in addition to combining multiple drugs within a nanocarrier. PubMed
47.
Panonnummal R, Sabitha M. Anti-psoriatic and toxicity evaluation of methotrexate loaded chitin nanogel in imiquimod induced mice model. Int J Biol Macromol. 2018;110:245–58.PubMed
48.
• Panonnummal R, Jayakumar R, Anjaneyan G, Sabitha M. In vivo anti-psoriatic activity, biodistribution, sub-acute and sub-chronic toxicity studies of orally administered methotrexate loaded chitin nanogel in comparison with methotrexate tablet. Int J Biol Macromol. 2018;110:259–68 A lower dose of oral methotrexate included in chitin nanogels reduced psoriasis symptoms in a murine model without causing liver and lung toxicities that were seen with higher doses of methotrexate nanogels and free methotrexate. PubMed
49.
Monteiro-Riviere NA. Skin penetration of engineered nanomaterials. In: Nasir A, Friedman A, Wang S, editors. Nanotechnology in dermatology. New York, NY: Springer New York; 2013. p. 51–61.
50.
Siddique MI, Katas H, Amin MCIM, Ng S-F, Zulfakar MH, Jamil A. In-vivo dermal pharmacokinetics, efficacy, and safety of skin targeting nanoparticles for corticosteroid treatment of atopic dermatitis. Int J Pharm. 2016;507:72–82.PubMed
51.
Wohlrab J, Goebel A, Scherer D, Bingham D, Newbert R A topical tacrolimus microemulsion for plaque-type psoriasis therapy. Drug Development & Delivery. 2012; June.
52.
Chlapanidas T, Perteghella S, Leoni F, Faragò S, Marazzi M, Rossi D, et al. TNF-α blocker effect of naringenin-loaded sericin microparticles that are potentially useful in the treatment of psoriasis. Int J Mol Sci. 2014;15:13624–36.PubMedPubMedCentral
53.
Krueger G, Ellis CN. Psoriasis—recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol. 2005;53:S94–S100.PubMed
54.
Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol. 1999;41:S7–S12.PubMed
55.
Draelos ZD. Enhancement of topical delivery with Nanocarriers. In: Nasir A, Friedman A, Wang S, editors. Nanotechnology in dermatology. New York, NY: Springer New York; 2013. p. 87–93.
56.
Cho Y, Lew B-L, Seong K, Kim N-I. An inverse relationship between ceramide synthesis and clinical severity in patients with psoriasis. J Korean Med Sci. 2004;19:859–63.PubMedPubMedCentral
57.
Lew B-L, Cho Y, Kim J, Sim W-Y, Kim N-I. Ceramides and cell signaling molecules in psoriatic epidermis: reduced levels of ceramides, PKC-α, and JNK. J Korean Med Sci. 2006;21:95–9.PubMedPubMedCentral
58.
Tokudome Y, Saito Y, Sato F, Kikuchi M, Hinokitani T, Goto K. Preparation and characterization of ceramide-based liposomes with high fusion activity and high membrane fluidity. Colloids Surf B: Biointerfaces. 2009;73:92–6.PubMed
59.
Agarwal R, Katare O, Vyas S. Preparation and in vitro evaluation of liposomal/niosomal delivery systems for antipsoriatic drug dithranol. Int J Pharm. 2001;228:43–52.PubMed
60.
Painsi C, Patscheider M, Inzinger M, Huegel R, Lange-Asschenfeldt B, Quehenberger F, et al. Psoriasis area and severity index 75 rate of classical inpatient dithranol therapy under daily life conditions. Br J Dermatol. 2015;173:815–7.PubMed
61.
Kemény L, Ruzicka T, Braun-Falco O. Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris. Skin Pharmacol. 1990;3:1–20.PubMed
62.
Assmann T, Ruzicka T. New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications. Clin Dermatol. 2002;20:505–14.PubMed
63.
Zonneveld IM, Rubins A, Jablonska S, Dobozy A, Ruzicka T, Kind P, et al. Topical tacrolimus is not effective in chronic plaque psoriasis. A pilot study. Arch Dermatol. 1998;134:1101–2.PubMed
64.
65.
Lui H. Phototherapy of psoriasis: update with practical pearls. J Cutan Med Surg. 2002;6:17–21.PubMed
66.
Zanolli M. Phototherapy treatment of psoriasis today. J Am Acad Dermatol. 2003;49:78–86.
67.
Stern RS. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet a therapy: a 30-year prospective study. J Am Acad Dermatol. 2012;66:553–62.PubMed
68.
Shaikh IM, Jadhav KR, Kadam VJ. Lecithin organogels in enhancing skin delivery of drugs. In: Dragicevic N, Maibach HI, editors. Percutaneous penetration enhancers chemical methods in penetration enhancement: drug manipulation strategies and vehicle effects. Berlin, Heidelberg: Springer Berlin Heidelberg; 2015. p. 299–313.
69.
Maza A, Montaudié H, Sbidian E, Gallini A, Aractingi S, Aubin F, et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 2):19–27.PubMed
70.
Griffiths CE. Systemic and local administration of cyclosporine in the treatment of psoriasis. J Am Acad Dermatol. 1990;23:1242–6 discussion 1246-1247.PubMed
71.
Jeffes EW, McCullough JL, Pittelkow MR, McCormick A, Almanzor J, Liu G, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol. 1995;104:183–8.PubMed
72.
McCullough JL, Snyder DS, Weinstein GD, Friedland A, Stein B. Factors affecting human percutaneous penetration of methotrexate and its analogues in vitro. J Investig Dermatol. 1976;66:103–7.PubMed
73.
Stewart WD, Wallace SM, Runikis JO. Absorption and local action of methotrexate in human and mouse skin. Arch Dermatol. 1972;106:357–61.PubMed
74.
Boyd AS, King LE. Tamoxifen-induced remission of psoriasis. J Am Acad Dermatol. 1999;41:887–9.PubMed
75.
Ferrari VD, Jirillo A. Psoriasis and tamoxifen therapy: a case report. Tumori. 1996;82:262–3.PubMed
76.
Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice. Curr Clin Pharmacol. 2013;8:135–55.PubMedPubMedCentral
77.
Boyd AS, Morris LF, Phillips CM, Menter MA. Psoriasis and pregnancy: hormone and immune system interaction. Int J Dermatol. 1996;35:169–72.PubMed
78.
Raghunath RS, Venables ZC, Millington GWM. The menstrual cycle and the skin. Clin Exp Dermatol. 2015;40:111–5.PubMed
79.
Cunningham M, Gilkeson G. Estrogen receptors in immunity and autoimmunity. Clin Rev Allergy Immunol. 2011;40:66–73.PubMed
80.
Zhao K, Singh S, Singh J. Effect of menthone on the in vitro percutaneous absorption of tamoxifen and skin reversibility. Int J Pharm. 2001;219:177–81.PubMed
81.
Raza K, Singh B, Mahajan A, Negi P, Bhatia A, Katare OP. Design and evaluation of flexible membrane vesicles (FMVs) for enhanced topical delivery of capsaicin. J Drug Target. 2011;19:293–302.PubMed
82.
de Jongh GJ, Zeeuwen PLJM, Kucharekova M, Pfundt R, van der Valk PG, Blokx W, et al. High expression levels of keratinocyte antimicrobial proteins in psoriasis compared with atopic dermatitis. J Invest Dermatol. 2005;125:1163–73.PubMed
83.
Geusens B, Van Gele M, Braat S, De Smedt SC, Stuart MCA, Prow TW, et al. Flexible nanosomes (SECosomes) enable efficient siRNA delivery in cultured primary skin cells and in the viable epidermis of ex vivo human skin. Adv Funct Mater. 2010;20:4077–90.
84.
Schneider MR, Werner S, Paus R, Wolf E. Beyond wavy hairs: the epidermal growth factor receptor and its ligands in skin biology and pathology. Am J Pathol. 2008;173:14–24.PubMedPubMedCentral
85.
Johnston A, Gudjonsson JE, Aphale A, Guzman AM, Stoll SW, Elder JT. EGFR and IL-1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation-dependent manner. J Invest Dermatol. 2011;131:329–37.PubMed
86.
Anderson KS, Petersson S, Wong J, Shubbar E, Lokko NN, Carlström M, et al. Elevation of serum epidermal growth factor and interleukin 1 receptor antagonist in active psoriasis vulgaris. Br J Dermatol. 2010;163:1085–9.PubMed
87.
Flisiak I, Szterling-Jaworowska M, Baran A, Rogalska-Taranta M. Effect of psoriasis activity on epidermal growth factor (EGF) and the concentration of soluble EGF receptor in serum and plaque scales. Clin Exp Dermatol. 2014;39:461–7.PubMed
88.
89.
Balasubramanian S, Eckert RL. Keratinocyte proliferation, differentiation, and apoptosis—differential mechanisms of regulation by curcumin, EGCG and apigenin. Toxicol Appl Pharmacol. 2007;224:214–9.PubMedPubMedCentral
90.
Hsu S, Dickinson D, Borke J, Walsh DS, Wood J, Qin H, et al. Green tea polyphenol induces caspase 14 in epidermal keratinocytes via MAPK pathways and reduces psoriasiform lesions in the flaky skin mouse model. Exp Dermatol. 2007;16:678–84.PubMed
91.
Krupkova O, Ferguson SJ, Wuertz-Kozak K. Stability of (−)-epigallocatechin gallate and its activity in liquid formulations and delivery systems. J Nutr Biochem. 2016;37:1–12.PubMed
92.
Elia R, Newhide DR, Pedevillano PD, Reiss GR, Firpo MA, Hsu EW, et al. Silk–hyaluronan-based composite hydrogels: a novel, securable vehicle for drug delivery. J Biomater Appl. 2011;27:749–62.PubMed
Metadaten
Titel
Nanotechnology for Psoriasis Therapy
verfasst von
Emily C. Murphy
Samuel W. Schaffter
Adam J. Friedman
Publikationsdatum
30.01.2019
Verlag
Springer US
Erschienen in
Current Dermatology Reports / Ausgabe 1/2019
Elektronische ISSN: 2162-4933
DOI
https://doi.org/10.1007/s13671-019-0248-y

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise